In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to EAPC Ivory (& above) Members, Fellows of the ESC and Young combined Members

Long-term management of cardiovascular risk factors in patients included in a cardiac rehabilitation unit

Session Poster Session 2

Speaker Carmen Rus Mansilla

Congress : ESC Preventive Cardiology (Formerly EuroPrevent) 2019

  • Topic : preventive cardiology
  • Sub-topic : Secondary Prevention
  • Session type : Poster Session
  • FP Number : P539

Authors : C Rus Mansilla (Andújar, Jaén,ES), G Cortez Quiroga (Andújar, Jaén,ES), MC Duran Torralba (Andújar, Jaén,ES), C Recuerda Casado (Andújar, Jaén,ES), MG Lopez Moyano (Andújar, Jaén,ES)

Authors:
C Rus Mansilla1 , G Cortez Quiroga1 , MC Duran Torralba1 , C Recuerda Casado1 , MG Lopez Moyano1 , 1Hospital Alto Guadalquivir, Cardiology - Andújar, Jaén - Spain ,

Citation:

Management of cardiovascular risk factors (CVRF) is far from optimal in patients with ischemic heart disease (IHD). Cardiac Rehabilitation programs (CRP) improve the management of CVRF in patients with IHD. The objective of this study is to compare the control of CVRF in patients who have received a comprehensive CRP versus those who did not
Methods: Patients from CRP were included from 2008 to 2018, within a county hospital. The comprehensive CRP consisted of three session/week during 12 weeks of physical exercise training and four educational talks. Long-term results were analyzed between patients who underwent (group 1) versus those who did not (group 2)
Results: The mean follow-up was 4.57 years. 79 (19%) of the 399 patients included were women, mean age 60 years old. The reason for inclusion was SCASEST in 51.9%. CVRF: 54% hypertension, 31% diabetic, 62% dyslipidemia, 51.4% smokers. 165 patients (41.1%) conform group 1 
At the last follow-up, there were no differences regarding the control of hypertension or HbA1c in diabetics. There were no patients who smoked in group 1 at follow-up, without statistically significant differences. Mean LDL in group 1 was 66.1 mg/dL, compared to group 2 (73.9 mg/dL), achieving optimal control of LDL in 66.9%, compared to 53,3% in group 2 (p <0.05), possibly due to greater use of ezetimibe in group 1 (50% vs 39.2%, p <0.05). The final mean body mass index (BMI) was >29 in both groups. The events were similar in both groups
Conclusions: The benefits of the inclusion in a comprehensive CRP are maintained long term, especially in lipid management, with a high percentage of patients who achieve goal, by adapting the available tools. However, the fact that including the patient in a CRP, although non-comprehensive, also shows encouraging results

Group 2

Non-comprehensive program

Group 1

Comprehensive program

BMI <25

15,3%

14,7%

p=n.s.

Patient achieving blood pression target

80,1%

80,9%

p=n.s.

Patient achieving heart rate target

73,5%

75,7%

p=n.s.

Smokers

0,5%

0,0%

p=n.s.

Patient achieving LDL target

53,3%

66,9%

p<0,05

High intensity statins

89,4%

91,9%

p=n.s.

Ezetimibe

39,2%

50,0%

p<0,05

Mean LDL (mg/dl)

73,9

66,1

p<0,05

Mean BMI

29,8

29,6

p=n.s.

Events (éxitus, ictus, síndrome coronario agudo o revascularización)

25,8%

18,4%

p=n.s.

Event: exitus, ictus, acute coronary syndrome or coronary revascularization

The free consultation period for this content is over.

It is now only available year-round to EAPC Ivory (& above) Members, Fellows of the ESC and Young combined Members



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are